DNK 333 hemihydrate | dual neurokinin NK1/NK2 receptor antagonist | CAS#1035662-71-5

MedKoo Cat#: 127135 | Name: DNK-333 hemihydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DNK 333 is a dual neurokinin NK1/NK2 receptor antagonist.

Chemical Structure

DNK-333 hemihydrate

CAS#1035662-71-5 (hemihydrate)

Theoretical Analysis

MedKoo Cat#: 127135

Name: DNK-333 hemihydrate

CAS#: 1035662-71-5 (hemihydrate)

Chemical Formula: C54H52Cl4F12N6O7

Exact Mass: 1264.2460

Molecular Weight: 1266.83

Elemental Analysis: C, 51.20; H, 4.14; Cl, 11.19; F, 18.00; N, 6.63; O, 8.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

398507-81-8 (free base) 1035662-71-5 (hemihydrate)

Synonym

DNK 333; DNK 333; DNK-333 hemihydrate

IUPAC/Chemical Name

N-((R,E)-1-(3,4-dichlorophenyl)-5-oxo-5-(((R)-2-oxoazepan-3-yl)amino)pent-3-en-2-yl)-N-methyl-3,5-bis(trifluoromethyl)benzamide hemihydrate

InChi Key

OONHVPMEYHFEDS-FELXCRFISA-N

InChi Code

InChI=1S/2C27H25Cl2F6N3O3.H2O/c2*1-38(25(41)16-12-17(26(30,31)32)14-18(13-16)27(33,34)35)19(10-15-5-7-20(28)21(29)11-15)6-8-23(39)37-22-4-2-3-9-36-24(22)40;/h2*5-8,11-14,19,22H,2-4,9-10H2,1H3,(H,36,40)(H,37,39);1H2/b2*8-6+;/t2*19-,22+;/m00./s1

SMILES Code

O.CN([C@H](CC1=CC(Cl)=C(Cl)C=C1)\C=C\C(=O)N[C@@H]2CCCCNC2=O)C(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F.CN([C@H](CC4=CC(Cl)=C(Cl)C=C4)\C=C\C(=O)N[C@@H]5CCCCNC5=O)C(=O)C6=CC(=CC(=C6)C(F)(F)F)C(F)(F)F

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,266.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zakko S, Barton G, Weber E, Dunger-Baldauf C, Rühl A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011 Jun;33(12):1311-21. doi: 10.1111/j.1365-2036.2011.04656.x. Epub 2011 Apr 20. PMID: 21507028. 2: Karmouty-Quintana H, Blé FX, Cannet C, Zurbruegg S, Fozard JR, Page CP, Beckmann N. In vivo pharmacological evaluation of compound 48/80-induced airways oedema by MRI. Br J Pharmacol. 2008 Jul;154(5):1063-72. doi: 10.1038/bjp.2008.174. Epub 2008 May 12. PMID: 18469845; PMCID: PMC2451044. 3: Joos GF, Vincken W, Louis R, Schelfhout VJ, Wang JH, Shaw MJ, Cioppa GD, Pauwels RA. Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81. doi: 10.1183/09031936.03.00101902. PMID: 14738235. 4: Karmouty-Quintana H, Cannet C, Sugar R, Fozard JR, Page CP, Beckmann N. Capsaicin-induced mucus secretion in rat airways assessed in vivo and non- invasively by magnetic resonance imaging. Br J Pharmacol. 2007 Apr;150(8):1022-30. doi: 10.1038/sj.bjp.0707168. Epub 2007 Mar 12. PMID: 17351665; PMCID: PMC2013907. 5: Tough IR, Lewis CA, Fozard J, Cox HM. Dual and selective antagonism of neurokinin NK(1) and NK(2) receptor-mediated responses in human colon mucosa. Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):104-8. doi: 10.1007/s00210-002-0671-6. Epub 2003 Jan 24. PMID: 12595950. 6: Gerspacher M, La Vecchia L, Mah R, von Sprecher A, Anderson GP, Subramanian N, Hauser K, Bammerlin H, Kimmel S, Pawelzik V, Ryffel K, Ball HA. Dual neurokinin NK(1)/NK(2) antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo- azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamides and 3-[N'-3,5-bis(trifluoromethyl)benzoyl-N- arylmethyl-N'-methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl]propionamides. Bioorg Med Chem Lett. 2001 Dec 3;11(23):3081-4. doi: 10.1016/s0960-894x(01)00631-x. PMID: 11714615. 7: Swarna VM, Undem BJ, Korlipara VL. Design and synthesis of 3,5-disubstituted benzamide analogues of DNK333 as dual NK1/NK2 receptor probes. Bioorg Med Chem Lett. 2007 Feb 15;17(4):890-4. doi: 10.1016/j.bmcl.2006.11.064. Epub 2006 Dec 1. PMID: 17169559. 8: Gerspacher M, Lewis C, Ball HA, Howes C, Subramanian N, Ryffel K, Fozard JR. Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist. J Med Chem. 2003 Jul 31;46(16):3508-13. doi: 10.1021/jm030786m. PMID: 12877589.